Complement Therapeutics secures Innovate UK EDGE funding to collaborate with the Cell and Gene Therapy Catapult on regulatory strategy for CTx001
- The Innovate UK EDGE grant funding is awarded to innovative companies looking to benefit from the expertise provided by Catapults or Research & Technology Organisations
- This grant funding further recognises the innovative nature of CTx001, a gene therapy being developed for the treatment of Geographic Atrophy.
London England – 17th November 2022 – Complement Therapeutics Ltd (CTx), a biotechnology company developing novel therapeutics for complement-related diseases, today announced a collaboration with the Cell and Gene Therapy (CGT) Catapult enabled by an Innovate UK EDGE grant funding award. This award allows CTx to benefit from the expertise within CGT Catapult’s Regulatory Affairs and Non-clinical Safety team to evaluate the Company’s non-clinical, chemistry manufacturing and control (CMC), quality and clinical development plans and define a tailored regulatory strategy for its lead product CTx001.
Dr. Rafiq Hasan, CEO at Complement Therapeutics commented: “We are delighted to receive the award from IUK for CTx001, highlighting the innovative potential of this gene therapy for the treatment of GA, a condition with significant unmet need. We look forward to continuing our collaboration with CGT Catapult, who have been an extended team to us since the formation of the Company, and we plan to strengthen our regulatory strategy through their deep understanding of the global regulatory landscape. CTx aims to maintain a constant dialogue with the regulators to ensure our lead candidate CTx001 reaches the clinic with a robust and validated development plan.’’
About Complement Therapeutics Ltd:
Complement Therapeutics (CTx) is an early-stage biotechnology company focused on the research and development of novel therapeutics for complement-mediated diseases. The Company is a spinout from the University of Manchester and is based on the pioneering research of its founders into novel targets within the complement cascade.
Our lead investigational product (CTx001) is being evaluated as a potential gene therapy for dry age-related macular degeneration/geographic atrophy, a leading cause of blindness. Additional programmes will evaluate potential therapeutic opportunities in other complement-mediated conditions.
The Company is also developing a unique quantification methodology, the Complement Precision Medicine (CPM) platform, to enable quantification of over 30 complement cascade proteins enabling more precise diagnosis and monitoring of disease.
About Cell and Gene Therapy Catapult:
The Cell and Gene Therapy Catapult is part of the Catapult Network. It was established by, and works in partnership with, Innovate UK.
The Cell and Gene Therapy Catapult is an independent innovation and technology organisation committed to the advancement of cell and gene therapies with a vision of a thriving industry delivering life changing advanced therapies to the world. Its aim is to create powerful collaborations which overcome challenges to the advancement of the sector. With over 400 experts covering all aspects of advanced therapies, it applies its unique capabilities and assets, collaborates with academia, industry and healthcare providers to develop new technology and innovation. For more information, please visit https:ct.catapult.org.uk or visit https://www.gov.uk/government/organisations/innovate-uk.
–The End–
For more information please visit: https://complementtx.com/
Company Contact
Dr Rafiq Hasan, CEO
Complement Therapeutics Ltd
Email: info@complementtx.com